cilostazol has been researched along with Disease Exacerbation in 30 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adult patients with noncardioembolic ischemic stroke within 24 hours after onset were randomized to receive cilostazol 200 mg/day (cilostazol group) or no medication (control group) in addition to the optimum medical treatments (a free radical scavenger plus an antiplatelet agent or an antithrombin agent)." | 9.17 | Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial. ( Kayama, T; Mizoi, K; Mori, E; Ogasawara, K; Ogawa, A; Saito, K; Shimizu, H; Terayama, Y; Tominaga, T, 2013) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 9.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 8.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "Our objective was to investigate the effect of cilostazol in acute therapy for small vessel stroke patients." | 7.80 | The effect of acute medication with cilostazol, an anti-platelet drug, on the outcome of small vessel brain infarction. ( Nakase, T; Sasaki, M; Suzuki, A, 2014) |
| "Cilostazol is an antiplatelet, antithrombotic agent with anti-inflammatory properties." | 6.79 | Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. ( Hsiao, FC; Hsieh, CH; Hung, YJ; Kuo, FC; Lee, CH; Lin, FH; Tang, WH, 2014) |
| "We performed a secondary analysis from the Cilostazol in Acute Ischemic Stroke Treatment (CAIST) trial, which was a double-blinded, randomized, multicenter trial, assessing the noninferiority of cilostazol over aspirin within 48 hours of an acute ischemic stroke." | 5.19 | Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. ( Bae, HJ; Kang, DW; Kwon, HM; Lee, YS, 2014) |
| "Adult patients with noncardioembolic ischemic stroke within 24 hours after onset were randomized to receive cilostazol 200 mg/day (cilostazol group) or no medication (control group) in addition to the optimum medical treatments (a free radical scavenger plus an antiplatelet agent or an antithrombin agent)." | 5.17 | Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial. ( Kayama, T; Mizoi, K; Mori, E; Ogasawara, K; Ogawa, A; Saito, K; Shimizu, H; Terayama, Y; Tominaga, T, 2013) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 5.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 4.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "Our previous trial acute dual study (ADS) reported that dual antiplatelet therapy (DAPT) using cilostazol and aspirin did not reduce the rate of short-term neurological worsening in non-cardioembolic stroke patients." | 4.02 | Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2021) |
| "Our objective was to investigate the effect of cilostazol in acute therapy for small vessel stroke patients." | 3.80 | The effect of acute medication with cilostazol, an anti-platelet drug, on the outcome of small vessel brain infarction. ( Nakase, T; Sasaki, M; Suzuki, A, 2014) |
| "Cilostazol treatment was associated with significantly lowered IMT in T2D patients compared to aspirin, independent of conventional cardiovascular risk factors." | 2.90 | Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness. ( Chun, M; Hong, S; Kang, J; Kim, D; Lee, K; Little, BB; Nam, M; Paik, S; Park, Y; Woo, J, 2019) |
| "Cilostazol is an antiplatelet, antithrombotic agent with anti-inflammatory properties." | 2.79 | Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. ( Hsiao, FC; Hsieh, CH; Hung, YJ; Kuo, FC; Lee, CH; Lin, FH; Tang, WH, 2014) |
| "Changes in atherosclerosis are more dynamic in patients with symptomatic ICAS, and the predictors of symptomatic and asymptomatic ICAS differ." | 2.79 | Predictors of symptomatic and asymptomatic intracranial atherosclerosis: what is different and why? ( Cho, YJ; Hong, KS; Kang, DW; Kim, BJ; Kim, JS; Koo, JS; Kwon, SU; Lee, JH; Lee, SH; Park, JM, 2014) |
| "Cilostazol was associated with a significant reduction in the progression of carotid IMT (WMD, -0." | 2.48 | Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. ( Deng, J; Geng, DF; Jin, DM; Wang, JF; Wu, W, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (26.67) | 29.6817 |
| 2010's | 21 (70.00) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, J | 1 |
| Iguchi, Y | 1 |
| Urabe, T | 1 |
| Yamagami, H | 1 |
| Todo, K | 1 |
| Fujimoto, S | 1 |
| Idomari, K | 1 |
| Kaneko, N | 1 |
| Iwanaga, T | 1 |
| Terasaki, T | 1 |
| Tanaka, R | 1 |
| Yamamoto, N | 1 |
| Tsujino, A | 1 |
| Nomura, K | 1 |
| Abe, K | 1 |
| Uno, M | 1 |
| Okada, Y | 1 |
| Matsuoka, H | 1 |
| Yamagata, S | 1 |
| Yamamoto, Y | 1 |
| Yonehara, T | 1 |
| Inoue, T | 1 |
| Yagita, Y | 2 |
| Kimura, K | 2 |
| Noh, Y | 1 |
| Lee, J | 1 |
| Shin, S | 1 |
| Park, I | 1 |
| Bae, SK | 1 |
| Oh, E | 1 |
| Lee, S | 1 |
| Saji, N | 1 |
| Tone, S | 1 |
| Murotani, K | 1 |
| Sakurai, T | 1 |
| Reddy, SS | 1 |
| Agarwal, H | 1 |
| Barthwal, MK | 1 |
| Hong, S | 1 |
| Nam, M | 1 |
| Little, BB | 1 |
| Paik, S | 1 |
| Lee, K | 1 |
| Woo, J | 1 |
| Kim, D | 1 |
| Kang, J | 1 |
| Chun, M | 1 |
| Park, Y | 1 |
| Shimizu, H | 1 |
| Tominaga, T | 1 |
| Ogawa, A | 1 |
| Kayama, T | 1 |
| Mizoi, K | 1 |
| Saito, K | 1 |
| Terayama, Y | 1 |
| Ogasawara, K | 1 |
| Mori, E | 1 |
| Tang, WH | 1 |
| Lin, FH | 1 |
| Lee, CH | 1 |
| Kuo, FC | 1 |
| Hsieh, CH | 1 |
| Hsiao, FC | 1 |
| Hung, YJ | 1 |
| Kim, SM | 1 |
| Cho, KI | 1 |
| Qian, Y | 1 |
| Bi, Q | 1 |
| Huh, JH | 1 |
| Seok, H | 1 |
| Lee, BW | 1 |
| Kang, ES | 1 |
| Lee, HC | 1 |
| Cha, BS | 1 |
| Kwon, HM | 1 |
| Lee, YS | 3 |
| Bae, HJ | 3 |
| Kang, DW | 3 |
| Nakase, T | 1 |
| Sasaki, M | 1 |
| Suzuki, A | 1 |
| Kim, BJ | 2 |
| Hong, KS | 3 |
| Cho, YJ | 3 |
| Lee, JH | 4 |
| Koo, JS | 3 |
| Park, JM | 2 |
| Kim, JS | 4 |
| Lee, SH | 2 |
| Kwon, SU | 3 |
| Kim, JH | 2 |
| Hong, KW | 1 |
| Bae, SS | 1 |
| Shin, YI | 1 |
| Choi, BT | 1 |
| Shin, HK | 1 |
| Hsieh, CJ | 1 |
| Wang, PW | 1 |
| Muñoz, B | 1 |
| Huerta, M | 1 |
| López-Bayghen, E | 1 |
| Shigematsu, H | 1 |
| Nishibe, T | 1 |
| Obitsu, Y | 1 |
| Matsuzaki, K | 1 |
| Ishida, A | 1 |
| Miyata, T | 1 |
| Shindo, S | 1 |
| Hida, K | 1 |
| Ohta, T | 1 |
| Ando, M | 1 |
| Kawasaki, T | 1 |
| Yasugi, T | 1 |
| Matsumoto, T | 1 |
| Olin, JW | 1 |
| Sealove, BA | 1 |
| Ahn, CM | 1 |
| Hong, SJ | 1 |
| Park, JH | 1 |
| Lim, DS | 1 |
| Ko, YG | 1 |
| Kim, BK | 1 |
| Lee, BK | 1 |
| Kang, WC | 1 |
| Choi, SH | 1 |
| Kim, SW | 1 |
| Lee, M | 1 |
| Honda, Y | 1 |
| Fitzerald, PJ | 1 |
| Shim, WH | 1 |
| Yu, KH | 1 |
| Wong, KS | 1 |
| Lee, KB | 1 |
| Kim, DE | 1 |
| Jeong, SW | 1 |
| Lee, BC | 1 |
| Han, MK | 1 |
| Rha, JH | 1 |
| Kim, HY | 1 |
| Mok, VC | 1 |
| Kim, GM | 1 |
| Suwanwela, NC | 1 |
| Yun, SC | 1 |
| Nah, HW | 1 |
| Geng, DF | 1 |
| Deng, J | 1 |
| Jin, DM | 1 |
| Wu, W | 1 |
| Wang, JF | 1 |
| Heo, SH | 1 |
| Lee, JS | 1 |
| Hwang, KJ | 1 |
| Chang, DI | 1 |
| Liu, W | 1 |
| Liu, R | 1 |
| Sun, W | 1 |
| Peng, Q | 1 |
| Zhang, W | 1 |
| Xu, E | 1 |
| Cheng, Y | 1 |
| Ding, M | 1 |
| Li, Y | 1 |
| Hong, Z | 1 |
| Wu, J | 1 |
| Zeng, J | 1 |
| Yao, C | 1 |
| Huang, Y | 1 |
| Hittel, N | 1 |
| Donnelly, R | 1 |
| Takahashi, K | 1 |
| Iijima, K | 1 |
| Nagasaki, M | 1 |
| Torii, I | 1 |
| Yamaguchi, S | 1 |
| Kobayashi, S | 1 |
| Suzuki, K | 1 |
| Uchida, K | 1 |
| Nakanishi, N | 1 |
| Hattori, Y | 1 |
| Hiatt, WR | 1 |
| Nehler, MR | 1 |
| Fernandez, BB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Cilostazol, a Phosphodiesterase 3 Inhibitor, on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes[NCT03248401] | Phase 4 | 50 participants (Actual) | Interventional | 2016-09-26 | Completed | ||
| [NCT01031667] | Phase 4 | 118 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel[NCT00130039] | Phase 4 | 457 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial[NCT00202020] | Phase 3 | 720 participants | Interventional | 2004-05-31 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Evaluation of the Effect of Cilostazol on the Clinical Outcomes of Rheumatoid Arthritis Patients[NCT05671497] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI. (NCT00130039)
Timeframe: 7 months after treatment
| Intervention | pariticipants (Number) |
|---|---|
| Cilostazol | 34 |
| Clopidogrel | 23 |
including nonfatal stroke, nonfatal myocardial infarction and vascular death. (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 15 |
| Clopidogrel | 10 |
"Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.~The progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA." (NCT00130039)
Timeframe: 7 months after treatment
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 20 |
| Clopidogrel | 32 |
including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 11 |
| Clopidogrel | 7 |
ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 9 |
| Clopidogrel | 5 |
life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | events (Number) |
|---|---|
| Cilostazol | 2 |
| Clopidogrel | 6 |
4 reviews available for cilostazol and Disease Exacerbation
| Article | Year |
|---|---|
Systematic study of cilostazol on secondary stroke prevention: a meta-analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Disease Progression; Humans; Incidenc | 2013 |
Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials.
Topics: Aged; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cilostazol; Disease Progression; Drug | 2012 |
Treating peripheral arterial disease in patients with diabetes.
Topics: Cilostazol; Diabetic Angiopathies; Disease Progression; Humans; Peripheral Vascular Diseases; Phosph | 2002 |
Peripheral arterial disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cilostazol; Diabetes Complications; Diabetes Mellitus; Dis | 2001 |
11 trials available for cilostazol and Disease Exacerbation
| Article | Year |
|---|---|
Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Carotid Intima-Media Thickness; Cilostazol | 2019 |
Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial.
Topics: Aged; Cilostazol; Disease Progression; Drug Therapy, Combination; Female; Fibrinolytic Agents; Free | 2013 |
Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Albuminuria; Anti-Inflammatory Agents; Chemokine CCL2; Cil | 2014 |
Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke.
Topics: Aged; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Protein; Cilostazol; Disease Progression; Doub | 2014 |
Predictors of symptomatic and asymptomatic intracranial atherosclerosis: what is different and why?
Topics: Aged; Arteries; Atherosclerosis; Cholesterol, HDL; Cilostazol; Constriction, Pathologic; Disease Pro | 2014 |
Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease.
Topics: Adiponectin; Aged; Aged, 80 and over; Ankle; Arterial Occlusive Diseases; Biomarkers; Blood Pressure | 2009 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona | 2011 |
Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Biomarkers; Cilostazol; Coronary Angiograp | 2011 |
Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.
Topics: Aged; Aged, 80 and over; Cilostazol; Clopidogrel; Constriction, Pathologic; Disease Progression; Dou | 2011 |
Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions.
Topics: Aspirin; Blood Pressure; Brain; Brain Diseases; Cerebral Hemorrhage; Cilostazol; Disease Progression | 2012 |
Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis.
Topics: Aged; Angiography; Arteries; Aspirin; Brain; Cilostazol; Constriction, Pathologic; Disease Progressi | 2005 |
15 other studies available for cilostazol and Disease Exacerbation
| Article | Year |
|---|---|
Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis.
Topics: Aged; Aspirin; Cilostazol; Disease Progression; Dual Anti-Platelet Therapy; Female; Humans; Japan; M | 2021 |
Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cilostazol; Cohort Studi | 2018 |
Cilostazol May Decrease Plasma Inflammatory Biomarkers in Patients with Recent Small Subcortical Infarcts: A Pilot Study.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Cerebral Infarction; Chi-Square Distribution; Cilostaz | 2018 |
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Topics: Angiotensin II; Animals; Biomarkers; Biopsy; Blood Pressure; Cilostazol; Diastole; Disease Models, A | 2018 |
Impact of cilostazol on the progression of carotid atherosclerosis in patients with retinal vascular occlusion.
Topics: Adult; Aged; Aged, 80 and over; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cilostazol; | 2013 |
Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event.
Topics: Aged; Cardiovascular Diseases; Carotid Arteries; Carotid Intima-Media Thickness; Cilostazol; Diabete | 2014 |
The effect of acute medication with cilostazol, an anti-platelet drug, on the outcome of small vessel brain infarction.
Topics: Aged; Aged, 80 and over; Brain Infarction; Cilostazol; Disease Progression; Female; Humans; Japan; M | 2014 |
Probucol plus cilostazol attenuate hypercholesterolemia‑induced exacerbation in ischemic brain injury via anti-inflammatory effects.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Brain Injuries; Brain Ischemia; CD11b Antigen; Cerebr | 2014 |
Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells.
Topics: Animals; Apoptosis; Base Sequence; Cell Cycle; Cell Line; Cell Proliferation; Cilostazol; Cyclic AMP | 2009 |
Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Topics: Adult; Aged; Aged, 80 and over; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular | 2010 |
Peripheral artery disease: current insight into the disease and its diagnosis and management.
Topics: Ankle Brachial Index; Cardiovascular Diseases; Cilostazol; Diagnosis, Differential; Disease Progress | 2010 |
Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients.
Topics: Adult; Aged; Analysis of Variance; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholester | 2013 |
Deterioration of vascular dementia caused by recurrent multiple small emboli from thoracic aortic atheroma.
Topics: Aged; Aorta, Thoracic; Arteriosclerosis; Cilostazol; Dementia, Vascular; Disease Progression; Emboli | 2004 |
Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes.
Topics: AMP-Activated Protein Kinases; Animals; Aorta; Blood Glucose; Blotting, Western; Cells, Cultured; Ch | 2008 |
A rational approach to diagnosis and treatment of intermittent claudication.
Topics: Algorithms; Blood Pressure Determination; Cilostazol; Disease Progression; Exercise Test; Hematologi | 2002 |